A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

PURPOSE: MET and AXL mediate resistance to EGFR TKI in NSCLC. Foretinib, a MET/RON/AXL/TIE-2/VEGFR kinase inhibitor may overcome EGFR kinase resistance. This dose escalation study combined foretinib and erlotinib in advanced pretreated NSCLC patients. EXPERIMENTAL DESIGN: The primary endpoint was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Leighl, Natasha B., Tsao, Ming-Sound, Liu, Geoffrey, Tu, Dongsheng, Ho, Cheryl, Shepherd, Frances A., Murray, Nevin, Goffin, John R., Nicholas, Garth, Sakashita, Shingo, Chen, Zhuo, Kim, Lucia, Powers, Jean, Seymour, Lesley, Goss, Glenwood, Bradbury, Penelope A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642506/
https://www.ncbi.nlm.nih.gov/pubmed/29050231
http://dx.doi.org/10.18632/oncotarget.18753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642506/
https://www.ncbi.nlm.nih.gov/pubmed/29050231
http://dx.doi.org/10.18632/oncotarget.18753

Ejemplares similares